Effective July 1, 2022, the Alabama Medicaid Agency will:   

  • Remove prior authorization (PA) from dexmethylphenidate ER (generic Focalin XR). Brand Focalin XR will now require PA.  
  • Update the PDL (Preferred Drug List) to reflect the quarterly updates listed below:   
PDL Additions 
Dexmethylphenidate ER (generic)  Cerebral Stimulants/Agents Used for ADHD (attention deficit hyperactivity disorder) (Long-Acting) 
PDL Deletions 
Adhansia XR  Cerebral Stimulants/ Agents Used for ADHD (Long-Acting) 
Focalin XR  Cerebral Stimulants/ Agents Used for ADHD (Long-Acting) 

               

For additional PDL and coverage information, visit the drug look-up site. 

The Prior Authorization (PA) request form and criteria booklet should be utilized by the prescriber or the dispensing pharmacy when requesting a PA. The PA request form can be completed and submitted electronically on the Agency’s website.  

Incomplete PA requests or those failing to meet Medicaid criteria will be denied. If the prescriber believes medical justification should be considered, the prescriber must document this on the form or submit a written letter of medical justification along with the PA form to Kepro. Additional information may be requested. Staff physicians will review this information. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.